Pharmaceutical companies GSK and Servier agreed at SPIEF to increase the production of a drug for the treatment of HIV infection at the Moscow factory “Servier RUS.” This was reported on Wednesday by the press service of the department of investment and industrial policy of the capital. “Within the framework of SPIEF, international pharmaceutical companies GSK and Servier agreed to increase the production of a drug for the treatment of HIV infection at the Moscow company Servier RUS. This will allow you to flexibly increase the production of medicines, taking into account the needs of the country’s health system, “the report said. On the part of GSK, the statement was signed by Sean Riley, vice president and CEO of GSK Pharma Russia, on the part of Servier, Christoph Wlodarczyk, general director of the Servier RUS pharmaceutical plant, signed his signature. “30 large and medium-sized pharmaceutical enterprises operate in Moscow. For the capital, this is one of the priority industries: already now 13% of the country’s family industry employees work with us, providing the production of 20% of medicines in Russia. The Moscow plant “Servier RUS” not only makes a significant contribution to the city economy, but also provides vital products. Back in 2016, the company was given the status of an industrial complex, which involves significant tax benefits. This helps the company increase the production of essential drugs, “said Alexander Prokhorov, head of the Department of Investment and Industrial Policy of Moscow.